Roche says divarasib cut risk of death 44% in lung cancer trial

Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced ​the risk of death by 44% compared ‌with existing treatments in a phase III study.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。